MOUNTAIN VIEW, Calif., Feb. 18, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Scott R. Ward as Chairman of its Board of Directors. Steven A. Elms, the incumbent Chairman and an original venture capital investor in the Company, will step down from the Board of Directors after over six years of service.
"I want to thank Steve for all his contributions to the Company and the Board as we have grown from an early concept to a late-stage development organization. I look forward to working with Scott as we prepare for our first NDA submission and potential product launch," said Timothy S. Nelson, MAP Pharmaceuticals' President and Chief Executive Officer. "Scott brings 30 years of industry and commercial experience and his leadership will be greatly valued as the Company continues to grow."
"I am pleased to take on the role of Chairman of the MAP Pharmaceuticals Board at this time, as the Company is transitioning into a commercial organization," said Scott R. Ward. "With the recently announced Allergan collaboration, the Company has established a strategic pathway for the potential commercialization of LEVADEX for the acute treatment of migraine."
Mr. Ward has extensive experience in the healthcare industry including 15 years as an operating business leader, and various roles in regulatory affairs, clinical research and business development since he joined Medtronic, Inc. in 1981. Mr. Ward has led the development and commercial launch of 20 significant new products and therapies in the cardiovascular and neurological markets.
Most recently, Mr. Ward was Senior Vice President and President of the CardioVascular business of Medtronic which generated approximately $3 billion in annual sales. He was responsible for all worldwide operations of the CardioVascular sector including the Coronary,